The Role of Human Endogenous Retroviruses in Cancer Immunotherapy of the Post-COVID-19 World

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Nov 25

PMID 38001581

Authors

Stella Logotheti

Thorsten Stiewe

Alexandros G Georgakilas

Affiliations

Soon will be listed here.

Abstract

At the outbreak of the COVID-19 global crisis, diverse scientific groups suggested that this unprecedented emergency could act as a 'blessing in disguise' [...].

References

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Ng K, Boumelha J, Enfield K, Almagro J, Cha H, Pich O . Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023; 616(7957):563-573. PMC: 10115647. DOI: 10.1038/s41586-023-05771-9. View

Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N . Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv. 2022; 8(4):eabj3671. PMC: 8791462. DOI: 10.1126/sciadv.abj3671. View

Li Y, Zhang G, Cui J . Origin and Deep Evolution of Human Endogenous Retroviruses in Pan-Primates. Viruses. 2022; 14(7). PMC: 9323773. DOI: 10.3390/v14071370. View

Gottschlich A, Thomas M, Grunmeier R, Lesch S, Rohrbacher L, Igl V . Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023; 41(11):1618-1632. PMC: 7615296. DOI: 10.1038/s41587-023-01684-0. View

Sun H, Zhang Y, Wang G, Yang W, Xu Y . mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics. 2023; 15(2). PMC: 9964383. DOI: 10.3390/pharmaceutics15020622. View

Saini S, Orskov A, Bjerregaard A, Unnikrishnan A, Holmberg-Thyden S, Borch A . Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nat Commun. 2020; 11(1):5660. PMC: 7653045. DOI: 10.1038/s41467-020-19464-8. View

Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G . Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines (Basel). 2023; 11(3). PMC: 10057252. DOI: 10.3390/vaccines11030636. View

Xavier C, Lopes C, Awni B, Campos E, Alves J, Camargo A . Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2022; 14(21). PMC: 9657500. DOI: 10.3390/cancers14215433. View

10.

Panda A, de Cubas A, Stein M, Riedlinger G, Kra J, Mayer T . Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight. 2018; 3(16). PMC: 6141170. DOI: 10.1172/jci.insight.121522. View

11.

Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R . MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. J Immunother Cancer. 2022; 10(3). PMC: 8919440. DOI: 10.1136/jitc-2021-004241. View

12.

Topham J, Titmuss E, Pleasance E, Williamson L, Karasinska J, Culibrk L . Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. Mol Cancer Ther. 2020; 19(9):1889-1897. DOI: 10.1158/1535-7163.MCT-20-0094. View

13.

Lorentzen C, Haanen J, Met O, Marie Svane I . Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022; 23(10):e450-e458. PMC: 9512276. DOI: 10.1016/S1470-2045(22)00372-2. View

14.

Daradoumis J, Ragonnaud E, Skandorff I, Nielsen K, Bermejo A, Andersson A . An Endogenous Retrovirus Vaccine Encoding an Envelope with a Mutated Immunosuppressive Domain in Combination with Anti-PD1 Treatment Eradicates Established Tumours in Mice. Viruses. 2023; 15(4). PMC: 10141008. DOI: 10.3390/v15040926. View

15.

Rivas S, Valdez M, Govindarajan V, Seetharam D, Doucet-OHare T, Heiss J . The Role of HERV-K in Cancer Stemness. Viruses. 2022; 14(9). PMC: 9504571. DOI: 10.3390/v14092019. View

16.

Bidram M, Zhao Y, Shebardina N, Baldin A, Bazhin A, Ganjalikhany M . mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines (Basel). 2021; 9(10). PMC: 8540049. DOI: 10.3390/vaccines9101060. View

17.

Huang Y, Zhao J, Soon Y, Kee A, Tay S, Aminkeng F . Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2023; 15(10). PMC: 10216169. DOI: 10.3390/cancers15102733. View

18.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

19.

Luksza M, Sethna Z, Rojas L, Lihm J, Bravi B, Elhanati Y . Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022; 606(7913):389-395. PMC: 9177421. DOI: 10.1038/s41586-022-04735-9. View

20.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View